About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The research group is focused on finding new molecular therapeutic targets and biomarkers based on knowledge of the biology of paediatric tumours, leukemias and hematologic diseases. The experience of the group in recent years has permitted the identification of new molecular targets that are very close to the clinical phase. In this stage, we have consolidated collaborations with the biotechnological industry in order to develop small molecules able to inhibit pro-oncogenic processes such as invasion or proliferation, with the aim of providing patients with innovative and more specific biological evidence-based therapies.
Another line of research is based on the study of liquid biopsy to develop a system based on NGS to monitor the probability of relapses.
Furthermore, we have implemented a personalized medicine program to guide the management of patients based on the molecular alterations of their tumours
PMID: 33661711 Journal: PEDIATRIC HEMATOLOGY AND ONCOLOGY Year: 2021 Reference: Pediatr Hematol Oncol. 2021 May;38(4):331-345. doi: 10.1080/08880018.2020.1868637. Epub 2021 Mar 4. Impact factor: 1.969 Publication type: Paper in international publication Authors: Mozo, Yasmina, Bueno, David, Sisinni, Luisa, Fernandez-Arroyo, Alba, Rosich, Blanca, Martinez, Antonio Perez, Uria, Maria Luz, Heredia, Cristina Diaz de, Mestre-Duran, Carmen, Pascual, Cristina Ferreras Barbara et al. DOI: 10.1080/08880018.2020.1868637
PMID: 33277309 Journal: Cancer Discovery Year: 2021 Reference: Cancer Discov. 2021 Mar;11(3):545-559. doi: 10.1158/2159-8290.CD-20-0779. Epub 2020 Dec 4. Impact factor: 39.397 Publication type: Review in international publication Authors: Laetsch, Theodore W, DuBois, Steven G, Bender, Julia Glade, Macy, Margaret E, Moreno, Lucas et al. DOI: 10.1158/2159-8290.CD-20-0779
PMID: 33613322 Journal: Frontiers in Physiology Year: 2021 Reference: Front Physiol. 2021 Feb 5;12:628236. doi: 10.3389/fphys.2021.628236. eCollection 2021. Impact factor: 4.566 Publication type: Paper in international publication Authors: Rizzuto, Valeria, Koopmann, Tamara T, Blanco-Alvarez, Adoracion, Tazon-Vega, Barbara, Idrizovic, Amira, Diaz de Heredia, Cristina, Del Orbe, Rafael, Pampliega, Miriam Vara, Velasco, Pablo, Santen, Gijs W E et al. DOI: 10.3389/fphys.2021.628236
PMID: 33602686 Journal: CLINICAL CANCER RESEARCH Year: 2021 Reference: Clin Cancer Res. 2021 May 1;27(9):2515-2522. doi: 10.1158/1078-0432.CCR-20-3677. Epub 2021 Feb 18. Impact factor: 12.531 Publication type: Paper in international publication Authors: Kudo, Toshihiro, Kagawa, Yoshinori, Fernandez, Elena Elez, Garcia-Foncillas, Jesus, Bando, Hideaki, Taniguchi, Hiroya, Vivancos, Ana, Akagi, Kiwamu, Garcia, Ariadna, Denda, Tadamichi et al. DOI: 10.1158/1078-0432.CCR-20-3677
PMID: 31738823 Journal: BLOOD Year: 2020 Reference: Blood. 2020 Jan 23;135(4):274-286. doi: 10.1182/blood.2019002699. Impact factor: 17.543 Publication type: Paper in international publication Authors: Azorin, Daniel, Ramis-Zaldivar, Joan Enric, Gonzalez-Farre, Blanca, Balague, Olga, Celis, Veronica, Nadeu, Ferran, Salmeron-Villalobos, Julia, Andres, Mara, Martin-Guerrero, Idoia, Garrido-Pontnou, Marta et al. DOI: 10.1182/blood.2019002699
PMID: 31939050 Journal: CANCER AND METASTASIS REVIEWS Year: 2020 Reference: Cancer Metastasis Rev. 2020 Mar;39(1):149-160. doi: 10.1007/s10555-020-09856-z. Impact factor: 6.4 Publication type: Review in international publication Authors: de Rojas, Teresa, Neven, Anouk, Towbin, Alexander J, Carceller, Fernando, Bautista, Francisco, Riedl, David, Sodergren, Samantha, Darlington, Anne-Sophie, Fernandez-Teijeiro, Ana, Moreno, Lucas et al. DOI: 10.1007/s10555-020-09856-z
PMID: 31908304 Journal: LANCET ONCOLOGY Year: 2020 Reference: Lancet Oncol. 2020 Jan;21(1):e3. doi: 10.1016/S1470-2045(19)30812-5. Impact factor: 33.752 Publication type: Letter or abstract Authors: Bisogno, Gianni, Ferrari, Andrea, Melcon, Soledad Gallego, De Salvo, Gian Luca, Bergeron, Christophe, Jenney, Meriel et al. DOI: 10.1016/S1470-2045(19)30812-5
PMID: 31625177 Journal: AMERICAN JOURNAL OF HEMATOLOGY Year: 2020 Reference: Am J Hematol. 2020 Jan;95(1):28-37. doi: 10.1002/ajh.25661. Epub 2019 Nov 5. Impact factor: 6.973 Publication type: Paper in international publication Authors: Diaz, Miguel Angel, de Heredia, Cristina Diaz, Perez-Martinez, Antonio, Ferreras, Cristina, Pascual, Antonia, Gonzalez-Vicent, Marta, Alonso, Laura, Badell, Isabel, Navarro, Jose Maria Fernandez, Regueiro, Alexandra et al. DOI: 10.1002/ajh.25661
The association, once again, has shown its commitment to oncological research with a donation of €19,197 to the Cancer and Hematological Diseases Group for Children at VHIR.
The prestigious journal The Lancet has published the results of this study, which is the result of more than 20 years of pre-clinical research and 7 years of patient follow-up.
During the meeting, the role of the Vall d'Hebron Paediatric Research Hub in promoting research on children and adolescents was highlighted.
